** Shares of drug developer Atea Pharmaceuticals AVIR.O rise 6.9% to $3.72 premarket
** Co says its drug combination met the main goal for treating Hepatitis C Virus (HCV) in a mid-stage study
** The combination of bemnifosbuvir and ruzasvir showed 98% success rate in eliminating HCV, co says
** Bemnifosbuvir and ruzasvir are both oral antiviral medications to treat HCV
** HCV is a leading cause of chronic liver diseases and liver transplants, affecting around 50 mln people worldwide
** As of last close, stock had risen 14.1% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。